ALSO NOTED: Alantos Pharmaceuticals inks deal with Servier; Millipore opens $50M R&D center; and much more...
> Alantos Pharmaceuticals of Cambridge, MA has signed a collaboration deal for its lead compound, ALS 2-0426 for Type 2 diabetes, with France's Servier. Alantos stands to gain $75 million in up front fees and milestones. Release
> Millipore has opened its $50 million R&D center in Bedford, MA. Release
> Chutes & Ladders: Threshold Pharmaceuticals CFO and COO Michael Ostrach is resigning his posts. Report
> Organon and BrainCells say they will collaborate on the development of new CNS drugs. Report
> ProNAi Therapeutics has arranged $6.65 million in bridge financing. Report
> Axial Biotech has raised a small round of venture capital. Report
> Wyeth has extended a deal that gives it access to Affymetrix's GeneChip microarray technology by three years. Report
And Finally… Inspired by a website, a rush of patients complaining of the same mysterious symptoms has spurred the CDC to see if two clusters are indeed the result of Morgellons disease. Article
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets